Annual Information Update

RNS Number : 2262E
Oxford Biomedica PLC
04 April 2011
 



Oxford BioMedica plc ("Oxford BioMedica" or the "Company")

 

Annual Information Update for the Twelve Months to 1 April 2011

 

Oxford BioMedica is providing an annual information update pursuant to Prospectus Rule 5.2 made by the Financial Services Authority.

 

1.                   Announcements made via a Regulatory Information Service

 

Date

Announcement



21 April 2010

Board Change - resignation of Nick Woolf

27 April 2010

AGM result

4 May 2010

Total voting rights update

5 May 2010

Holding(s) in Company

13 May 2010

Corporate presentation at Rodman & Renshaw conference

19 May 2010

Interim management statement

27 May 2010

Blocklisting interim review

14 June 2010

ProSavin® clinical trial update

15 June 2010

Directors' interests in shares - Long Term Incentive Plan award

17 June 2010

Holding(s) in Company

18 June 2010

Amendment to 5T4 licence with Cancer Research Technology  and issue of shares

24 June 2010

Collaboration to evaluate TroVax® in mesothelioma

24 June 2010

Notice of interim results

30 June 2010

Total voting rights update

1 July 2010

Notice of R&D presentation for investors and analysts

1 July 2010

Award of grant by Motor Neurone Disease Association

26 July 2010

FDA approval for TroVax® Phase II study in prostate cancer

18 August 2010

Licence agreement with Emergent BioSolutions Inc.

18 August 2010

Holding(s) in Company

24 August 2010

Interim results

15 September 2010

Holding(s) in Company

22 September 2010

TroVax® selected by Windhover and Campbell Alliance as one of the "Top 10 Most interesting Oncology Projects to Watch". 

14 October 2010

TroVax® Phase III data published in  journal Clinical Cancer Research

14 October 2010

Change of Advisor and Broker

29 October 2010

Interim management statement

9 November 2010

US IND approval for RetinoStat®

26 November 2010

Blocklisting interim review

13 December 2010

Proposed Firm Placing and Placing and Open Offer of up to £20 million

13 December 2010

Confirmation of underwritten £20 million share issue

14 December 2010

Issue of prospectus

22 December 2010

ProSavin® clinical trial update

23 December 2010

Corporate presentation at JP Morgan Healthcare conference

7 January 2011

Result of Open Offer

7 January 2011

Result of General Meeting

10 January 2011

Directors' interests in shares

12 January 2011

Holding(s) in Company

20 January 2011

Notice of results

31 January 2011

Acquisition of manufacturing facility

31 January 2011

Holding(s) in Company

31 January 2011

Total voting rights update

9 February 2011

Appointment of Head of Manufacturing

2 March 2011

Preliminary results for 2010

15 March 2011

TroVax® Phase III data published in  journal  Cancer Immunology, Immunotherapy

21 March 2011

US IND approval for StarGen™

21 March 2011

Board Change - resignation of Dr Alan Kingsman

22 March 2011

Director's interest in shares

31 March 2011

Annual Report and Accounts and AGM notification

1 April 2011

Annual information update

 

 

Details of all regulatory announcements for Oxford BioMedica can be found on the London Stock Exchange website at www.londonstockexchange.com  and on the Oxford BioMedica website at http://www.oxfordbiomedica.co.uk 

 

2.                  Documents filed with Companies House

 

Date

Document Type

Description




6 April 2010

SH01 Return of Allotments of Shares

Allotment 1,873,206 1p Ord.

27 April 2010

AGM Special Business

AGM minutes

28 June 2010

SH01 Return of Allotments of Shares

Allotment 1,816,523 1p Ord.

30 September 2010

AR01 Annual Return

Annual return

10 January 2011

SH01 Return of Allotments of Shares

Allotment 400,000,000 1p Ord.

 

Copies of documents filed at Companies House can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ or through Companies House Direct at www.direct.companieshouse.gov.uk 

 

3.                  Documents published or sent to shareholders or filed with the UKLA National Storage Mechanism

 

Date

Description

24 August 2010

Interim Report for 6 months to 30 June 2010

13 December 2010

Prospectus

7 January 2011

General Meeting Resolutions

30 March 2011

Annual report for the year ended 31 December 2010 and Notice of AGM

 

 

Copies of all the above documents may be obtained from the Company Secretary at the Company's Registered Office:

 

This annual information update is filed pursuant to Prospectus Rule 5.2 made by the Financial Services Authority and not for any other purpose and by filing this annual information update neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained or referred to below herein. The information referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Furthermore, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to below constitutes, by virtue of this communication, an offer of any securities addressed to any person and should not be relied on by any person.

 

 

 

Oxford BioMedica plc

Medawar Centre

Robert Robinson Avenue

The Oxford Science Park

Oxford

OX4 4GA

 

04 April 2011


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

AIUKZLBBFZFLBBQ